Search
Now showing items 1-10 of 206
Overview of microbicides for the prevention of human immunodeficiency virus.
(Elsevier., 2012)
Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four ...
Challenging racial stereotyping of AIDS in South Africa with prevalence of HIV in pregnant women.
(South African Medical Association / Health & Medical Publications Group., 2007)
No abstract available.
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
(Elsevier., 2012)
No abstract available.
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy.
(Oxford University Press., 2013)
Background. Eight decades ago, the ratio of monocytes to lymphocytes (hereafter, the “ML ratio”) was noted to affect outcomes of mycobacterial infection in rabbits. Recent transcriptomic studies support a role for relative ...
Medical education after the first decade of democracy in South Africa.
(Elsevier., 2004)
No abstract available.
HIV vaccines and immunity.
(Allergy Society of South Africa., 2003)
No abstract available.
An adaptive design to bridge the gap between phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
(Sage., 2012)
Background. Vaginally and rectally applied microbicides are being developed to
help prevent sexual acquisition of HIV. Due to the lack of surrogate outcomes, the
path toward licensure typically moves directly from expanded ...
Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies.
(Lippincott Williams & Wilkins., 2012)
Recent successes of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV infection
have raised questions whether further placebo controlled trials of new HIV-prevention
technologies are ethically justifiable. ...
Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial: response to O’Hagan et al.
(Lippincott Williams & Wilkins., 2012)
No abstract available.
Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
(Oxford University Press., 2011)
The antiretroviral agent, tenofovir, formulated as a vaginal microbicide gel, reduces human immunodeficiency
virus (HIV) acquisition by 39% in women. This study assessed the role of preexisting immune activation
in ...